"The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-ap"...
(Generic versions may still be available.)
- Patient Information:
Details with Side Effects
Testolactone is contraindicated in the treatment of breast cancer in men and in patients with a history of hypersensitivity to the drug.
Last reviewed on RxList: 6/30/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Teslac Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.